Progentos Therapeutics Doses First Participant in PRO-1562 Trial
Progentos Therapeutics says it has dosed the first participant in a Phase 1/2a trial of its multiple sclerosis drug PRO-1562.
Related stories
ICAPE Reports Q3 2026 Revenue of €68.7 Million
M impact | EQUITY | Nov 03, 2026, 06:33 PM UTC
Herbalife Publishes Q3 2026 Earnings Call Transcript
The transcript notes that Herbalife raised its 2026 reported sales guidance; the provided text is truncated.
M impact | EQUITY | Nov 03, 2026, 06:32 PM UTC
Barclays Runs Sale Process for Exeter Finance’s Nonprime Auto Loans
Barclays is running a sale process for up to $1 billion of Exeter Finance’s nonprime auto loans.
M impact | EQUITY | Nov 03, 2026, 06:30 PM UTC
US session market picture: S&P 500 +0.53%, Nasdaq 100 +0.87%; EUR/USD +0.09%, WTI -0.43%, WBD leads volume
US session market picture. US index futures: S and P futures is up 0.53 percent, Nasdaq futures is up 0.87 percent, Dow futures is down 0.27 percent and Russell futures is up 0.69
M impact | EQUITY | Nov 03, 2026, 06:30 PM UTC
American Honda Sales Rise 8% in October
Honda Motor's American Honda unit reported an 8% sales rise in October.
L impact | EQUITY | Nov 03, 2026, 06:29 PM UTC
Campine Agrees to Acquire Minority Stake in Thailand’s Green Tech Antimony
M impact | EQUITY | Nov 03, 2026, 06:29 PM UTC